Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 81

1.

Tau and atrophy: domain-specific relationships with cognition.

Digma LA, Madsen JR, Reas ET, Dale AM, Brewer JB, Banks SJ; Alzheimer’s Disease Neuroimaging Initiative.

Alzheimers Res Ther. 2019 Jul 27;11(1):65. doi: 10.1186/s13195-019-0518-8.

2.

Effect of AZD0530 on Cerebral Metabolic Decline in Alzheimer Disease: A Randomized Clinical Trial.

van Dyck CH, Nygaard HB, Chen K, Donohue MC, Raman R, Rissman RA, Brewer JB, Koeppe RA, Chow TW, Rafii MS, Gessert D, Choi J, Turner RS, Kaye JA, Gale SA, Reiman EM, Aisen PS, Strittmatter SM.

JAMA Neurol. 2019 Jul 22. doi: 10.1001/jamaneurol.2019.2050. [Epub ahead of print]

3.

Safety and Efficacy of Edonerpic Maleate for Patients With Mild to Moderate Alzheimer Disease: A Phase 2 Randomized Clinical Trial.

Schneider LS, Thomas RG, Hendrix S, Rissman RA, Brewer JB, Salmon DP, Oltersdorf T, Okuda T, Feldman HH; Alzheimer’s Disease Cooperative Study TCAD Study Group.

JAMA Neurol. 2019 Jul 8. doi: 10.1001/jamaneurol.2019.1868. [Epub ahead of print]

4.

Distinct structural correlates of the dominant and nondominant languages in bilinguals with Alzheimer's disease (AD).

Smirnov DS, Stasenko A, Salmon DP, Galasko D, Brewer JB, Gollan TH.

Neuropsychologia. 2019 Sep;132:107131. doi: 10.1016/j.neuropsychologia.2019.107131. Epub 2019 Jul 1.

PMID:
31271821
5.

Combined Biomarker Prognosis of Mild Cognitive Impairment: An 11-Year Follow-Up Study in the Alzheimer's Disease Neuroimaging Initiative.

Spencer BE, Jennings RG, Brewer JB; Alzheimer’s Disease Neuroimaging Initiative.

J Alzheimers Dis. 2019;68(4):1549-1559. doi: 10.3233/JAD-181243.

PMID:
30958366
6.

Trajectories of cognitive decline differ in hippocampal sclerosis and Alzheimer's disease.

Smirnov DS, Galasko D, Hansen LA, Edland SD, Brewer JB, Salmon DP.

Neurobiol Aging. 2019 Mar;75:169-177. doi: 10.1016/j.neurobiolaging.2018.11.015. Epub 2018 Nov 22.

PMID:
30579145
7.

Dissecting the genetic relationship between cardiovascular risk factors and Alzheimer's disease.

Broce IJ, Tan CH, Fan CC, Jansen I, Savage JE, Witoelar A, Wen N, Hess CP, Dillon WP, Glastonbury CM, Glymour M, Yokoyama JS, Elahi FM, Rabinovici GD, Miller BL, Mormino EC, Sperling RA, Bennett DA, McEvoy LK, Brewer JB, Feldman HH, Hyman BT, Pericak-Vance M, Haines JL, Farrer LA, Mayeux R, Schellenberg GD, Yaffe K, Sugrue LP, Dale AM, Posthuma D, Andreassen OA, Karch CM, Desikan RS.

Acta Neuropathol. 2019 Feb;137(2):209-226. doi: 10.1007/s00401-018-1928-6. Epub 2018 Nov 9.

8.

Clinical-Neuropathological Correlations of Alzheimer's Disease and Related Dementias in Latino Volunteers.

Soria JA, Huisa BN, Edland SD, Litvan I, Peavy GM, Salmon DP, Hansen LA, Galasko DR, Brewer JB, González HM, Rissman RA.

J Alzheimers Dis. 2018;66(4):1539-1548. doi: 10.3233/JAD-180789.

PMID:
30412501
9.

Microstructural brain changes track cognitive decline in mild cognitive impairment.

Reas ET, Hagler DJ Jr, White NS, Kuperman JM, Bartsch H, Wierenga CE, Galasko D, Brewer JB, Dale AM, McEvoy LK.

Neuroimage Clin. 2018;20:883-891. doi: 10.1016/j.nicl.2018.09.027. Epub 2018 Sep 26.

10.

Adeno-Associated Viral Vector (Serotype 2)-Nerve Growth Factor for Patients With Alzheimer Disease: A Randomized Clinical Trial.

Rafii MS, Tuszynski MH, Thomas RG, Barba D, Brewer JB, Rissman RA, Siffert J, Aisen PS; AAV2-NGF Study Team.

JAMA Neurol. 2018 Jul 1;75(7):834-841. doi: 10.1001/jamaneurol.2018.0233.

11.

Precision medicine screening using whole-genome sequencing and advanced imaging to identify disease risk in adults.

Perkins BA, Caskey CT, Brar P, Dec E, Karow DS, Kahn AM, Hou YC, Shah N, Boeldt D, Coughlin E, Hands G, Lavrenko V, Yu J, Procko A, Appis J, Dale AM, Guo L, Jönsson TJ, Wittmann BM, Bartha I, Ramakrishnan S, Bernal A, Brewer JB, Brewerton S, Biggs WH, Turpaz Y, Venter JC.

Proc Natl Acad Sci U S A. 2018 Apr 3;115(14):3686-3691. doi: 10.1073/pnas.1706096114. Epub 2018 Mar 19.

12.

Polygenic hazard score: an enrichment marker for Alzheimer's associated amyloid and tau deposition.

Tan CH, Fan CC, Mormino EC, Sugrue LP, Broce IJ, Hess CP, Dillon WP, Bonham LW, Yokoyama JS, Karch CM, Brewer JB, Rabinovici GD, Miller BL, Schellenberg GD, Kauppi K, Feldman HA, Holland D, McEvoy LK, Hyman BT, Bennett DA, Andreassen OA, Dale AM, Desikan RS; Alzheimer’s Disease Neuroimaging Initiative.

Acta Neuropathol. 2018 Jan;135(1):85-93. doi: 10.1007/s00401-017-1789-4. Epub 2017 Nov 24.

13.

Sensitivity of restriction spectrum imaging to memory and neuropathology in Alzheimer's disease.

Reas ET, Hagler DJ Jr, White NS, Kuperman JM, Bartsch H, Cross K, Loi RQ, Balachandra AR, Meloy MJ, Wierenga CE, Galasko D, Brewer JB, Dale AM, McEvoy LK.

Alzheimers Res Ther. 2017 Aug 2;9(1):55. doi: 10.1186/s13195-017-0281-7.

14.

A phase 3 trial of IV immunoglobulin for Alzheimer disease.

Relkin NR, Thomas RG, Rissman RA, Brewer JB, Rafii MS, van Dyck CH, Jack CR, Sano M, Knopman DS, Raman R, Szabo P, Gelmont DM, Fritsch S, Aisen PS; Alzheimer's Disease Cooperative Study.

Neurology. 2017 May 2;88(18):1768-1775. doi: 10.1212/WNL.0000000000003904. Epub 2017 Apr 5.

15.

Cerebral Cortex Regions Selectively Vulnerable to Radiation Dose-Dependent Atrophy.

Seibert TM, Karunamuni R, Kaifi S, Burkeen J, Connor M, Krishnan AP, White NS, Farid N, Bartsch H, Murzin V, Nguyen TT, Moiseenko V, Brewer JB, McDonald CR, Dale AM, Hattangadi-Gluth JA.

Int J Radiat Oncol Biol Phys. 2017 Apr 1;97(5):910-918. doi: 10.1016/j.ijrobp.2017.01.005. Epub 2017 Jan 6.

16.

Genetic assessment of age-associated Alzheimer disease risk: Development and validation of a polygenic hazard score.

Desikan RS, Fan CC, Wang Y, Schork AJ, Cabral HJ, Cupples LA, Thompson WK, Besser L, Kukull WA, Holland D, Chen CH, Brewer JB, Karow DS, Kauppi K, Witoelar A, Karch CM, Bonham LW, Yokoyama JS, Rosen HJ, Miller BL, Dillon WP, Wilson DM, Hess CP, Pericak-Vance M, Haines JL, Farrer LA, Mayeux R, Hardy J, Goate AM, Hyman BT, Schellenberg GD, McEvoy LK, Andreassen OA, Dale AM.

PLoS Med. 2017 Mar 21;14(3):e1002258. doi: 10.1371/journal.pmed.1002258. eCollection 2017 Mar. Erratum in: PLoS Med. 2017 Mar 28;14 (3):e1002289.

17.

I know I've seen you before: Distinguishing recent-single-exposure-based familiarity from pre-existing familiarity.

Gimbel SI, Brewer JB, Maril A.

Brain Res. 2017 Mar 1;1658:11-24. doi: 10.1016/j.brainres.2017.01.007. Epub 2017 Jan 7.

18.

Radiation Dose-Dependent Hippocampal Atrophy Detected With Longitudinal Volumetric Magnetic Resonance Imaging.

Seibert TM, Karunamuni R, Bartsch H, Kaifi S, Krishnan AP, Dalia Y, Burkeen J, Murzin V, Moiseenko V, Kuperman J, White NS, Brewer JB, Farid N, McDonald CR, Hattangadi-Gluth JA.

Int J Radiat Oncol Biol Phys. 2017 Feb 1;97(2):263-269. doi: 10.1016/j.ijrobp.2016.10.035. Epub 2016 Oct 31.

19.

Genetic architecture of sporadic frontotemporal dementia and overlap with Alzheimer's and Parkinson's diseases.

Ferrari R, Wang Y, Vandrovcova J, Guelfi S, Witeolar A, Karch CM, Schork AJ, Fan CC, Brewer JB; International FTD-Genomics Consortium (IFGC),; International Parkinson's Disease Genomics Consortium (IPDGC),; International Genomics of Alzheimer's Project (IGAP),, Momeni P, Schellenberg GD, Dillon WP, Sugrue LP, Hess CP, Yokoyama JS, Bonham LW, Rabinovici GD, Miller BL, Andreassen OA, Dale AM, Hardy J, Desikan RS.

J Neurol Neurosurg Psychiatry. 2017 Feb;88(2):152-164. doi: 10.1136/jnnp-2016-314411. Epub 2016 Nov 29.

20.

Demonstration of safety of intravenous immunoglobulin in geriatric patients in a long-term, placebo-controlled study of Alzheimer's disease.

Gelmont D, Thomas RG, Britt J, Dyck-Jones JA, Doralt J, Fritsch S, Brewer JB, Rissman RA, Aisen P.

Alzheimers Dement (N Y). 2016 Jun 21;2(2):131-139. doi: 10.1016/j.trci.2016.06.003. eCollection 2016 Jun.

21.

Association Between Genetic Traits for Immune-Mediated Diseases and Alzheimer Disease.

Yokoyama JS, Wang Y, Schork AJ, Thompson WK, Karch CM, Cruchaga C, McEvoy LK, Witoelar A, Chen CH, Holland D, Brewer JB, Franke A, Dillon WP, Wilson DM, Mukherjee P, Hess CP, Miller Z, Bonham LW, Shen J, Rabinovici GD, Rosen HJ, Miller BL, Hyman BT, Schellenberg GD, Karlsen TH, Andreassen OA, Dale AM, Desikan RS; Alzheimer’s Disease Neuroimaging Initiative.

JAMA Neurol. 2016 Jun 1;73(6):691-7. doi: 10.1001/jamaneurol.2016.0150.

22.

Dose-Dependent Cortical Thinning After Partial Brain Irradiation in High-Grade Glioma.

Karunamuni R, Bartsch H, White NS, Moiseenko V, Carmona R, Marshall DC, Seibert TM, McDonald CR, Farid N, Krishnan A, Kuperman J, Mell L, Brewer JB, Dale AM, Hattangadi-Gluth JA.

Int J Radiat Oncol Biol Phys. 2016 Feb 1;94(2):297-304. doi: 10.1016/j.ijrobp.2015.10.026. Epub 2015 Oct 21.

23.

The down syndrome biomarker initiative (DSBI) pilot: proof of concept for deep phenotyping of Alzheimer's disease biomarkers in down syndrome.

Rafii MS, Wishnek H, Brewer JB, Donohue MC, Ness S, Mobley WC, Aisen PS, Rissman RA.

Front Behav Neurosci. 2015 Sep 14;9:239. doi: 10.3389/fnbeh.2015.00239. eCollection 2015.

24.

A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease.

Turner RS, Thomas RG, Craft S, van Dyck CH, Mintzer J, Reynolds BA, Brewer JB, Rissman RA, Raman R, Aisen PS; Alzheimer's Disease Cooperative Study.

Neurology. 2015 Oct 20;85(16):1383-91. doi: 10.1212/WNL.0000000000002035. Epub 2015 Sep 11.

25.

Polygenic Overlap Between C-Reactive Protein, Plasma Lipids, and Alzheimer Disease.

Desikan RS, Schork AJ, Wang Y, Thompson WK, Dehghan A, Ridker PM, Chasman DI, McEvoy LK, Holland D, Chen CH, Karow DS, Brewer JB, Hess CP, Williams J, Sims R, O'Donovan MC, Choi SH, Bis JC, Ikram MA, Gudnason V, DeStefano AL, van der Lee SJ, Psaty BM, van Duijn CM, Launer L, Seshadri S, Pericak-Vance MA, Mayeux R, Haines JL, Farrer LA, Hardy J, Ulstein ID, Aarsland D, Fladby T, White LR, Sando SB, Rongve A, Witoelar A, Djurovic S, Hyman BT, Snaedal J, Steinberg S, Stefansson H, Stefansson K, Schellenberg GD, Andreassen OA, Dale AM; Inflammation working group, IGAP and DemGene Investigators.

Circulation. 2015 Jun 9;131(23):2061-2069. doi: 10.1161/CIRCULATIONAHA.115.015489. Epub 2015 Apr 10.

26.

Genetic overlap between Alzheimer's disease and Parkinson's disease at the MAPT locus.

Desikan RS, Schork AJ, Wang Y, Witoelar A, Sharma M, McEvoy LK, Holland D, Brewer JB, Chen CH, Thompson WK, Harold D, Williams J, Owen MJ, O'Donovan MC, Pericak-Vance MA, Mayeux R, Haines JL, Farrer LA, Schellenberg GD, Heutink P, Singleton AB, Brice A, Wood NW, Hardy J, Martinez M, Choi SH, DeStefano A, Ikram MA, Bis JC, Smith A, Fitzpatrick AL, Launer L, van Duijn C, Seshadri S, Ulstein ID, Aarsland D, Fladby T, Djurovic S, Hyman BT, Snaedal J, Stefansson H, Stefansson K, Gasser T, Andreassen OA, Dale AM; ADNI, ADGC, GERAD, CHARGE and IPDGC Investigators.

Mol Psychiatry. 2015 Dec;20(12):1588-95. doi: 10.1038/mp.2015.6. Epub 2015 Feb 17.

27.

Mean signal and response time influences on multivoxel signals of contextual retrieval in the medial temporal lobe.

Reas ET, Brewer JB.

Brain Behav. 2015 Feb;5(2):e00302. doi: 10.1002/brb3.302. Epub 2014 Dec 24.

28.

Prospective longitudinal MRI study of brain volumes and diffusion changes during the first year after moderate to severe traumatic brain injury.

Brezova V, Moen KG, Skandsen T, Vik A, Brewer JB, Salvesen O, Håberg AK.

Neuroimage Clin. 2014 Mar 28;5:128-40. doi: 10.1016/j.nicl.2014.03.012. eCollection 2014.

29.
30.

The role of clusterin in amyloid-β-associated neurodegeneration.

Desikan RS, Thompson WK, Holland D, Hess CP, Brewer JB, Zetterberg H, Blennow K, Andreassen OA, McEvoy LK, Hyman BT, Dale AM; Alzheimer’s Disease Neuroimaging Initiative Group.

JAMA Neurol. 2014 Feb;71(2):180-7. doi: 10.1001/jamaneurol.2013.4560.

31.

Neuropsychiatric symptoms and regional neocortical atrophy in mild cognitive impairment and Alzheimer's disease.

Rafii MS, Taylor CS, Kim HT, Desikan RS, Fleisher AS, Katibian D, Brewer JB, Dale AM, Aisen PS.

Am J Alzheimers Dis Other Demen. 2014 Mar;29(2):159-65. doi: 10.1177/1533317513507373. Epub 2013 Oct 27.

32.

Heart fatty acid binding protein and Aβ-associated Alzheimer's neurodegeneration.

Desikan RS, Thompson WK, Holland D, Hess CP, Brewer JB, Zetterberg H, Blennow K, Andreassen OA, McEvoy LK, Hyman BT, Dale AM; Alzheimer’s Disease Neuroimaging Initiative.

Mol Neurodegener. 2013 Oct 2;8:39. doi: 10.1186/1750-1326-8-39.

33.

Imbalance of incidental encoding across tasks: an explanation for non-memory-related hippocampal activations?

Reas ET, Brewer JB.

J Exp Psychol Gen. 2013 Nov;142(4):1171-9. doi: 10.1037/a0033461. Epub 2013 Jun 17.

34.

An expanded role for neuroimaging in the evaluation of memory impairment.

Desikan RS, Rafii MS, Brewer JB, Hess CP.

AJNR Am J Neuroradiol. 2013 Nov-Dec;34(11):2075-82. doi: 10.3174/ajnr.A3644. Epub 2013 Jun 13.

35.
36.

Effortful retrieval reduces hippocampal activity and impairs incidental encoding.

Reas ET, Brewer JB.

Hippocampus. 2013 May;23(5):367-79. doi: 10.1002/hipo.22096. Epub 2013 Feb 2.

37.

Erratum: search-related suppression of hippocampus and default network activity during associative memory retrieval.

Reas ET, Gimbel SI, Hales JB, Brewer JB.

Front Hum Neurosci. 2013 Jan 24;7:2. doi: 10.3389/fnhum.2013.00002. eCollection 2013. No abstract available.

38.

Parietal and frontal contributions to episodic encoding of location.

Hales JB, Brewer JB.

Behav Brain Res. 2013 Apr 15;243:16-20. doi: 10.1016/j.bbr.2012.12.048. Epub 2013 Jan 4.

39.

Retrieval search and strength evoke dissociable brain activity during episodic memory recall.

Reas ET, Brewer JB.

J Cogn Neurosci. 2013 Feb;25(2):219-33. doi: 10.1162/jocn_a_00335. Epub 2012 Nov 28.

40.

Apolipoprotein E epsilon4 does not modulate amyloid-β-associated neurodegeneration in preclinical Alzheimer disease.

Desikan RS, McEvoy LK, Holland D, Thompson WK, Brewer JB, Aisen PS, Andreassen OA, Hyman BT, Sperling RA, Dale AM; Alzheimer's Disease Neuroimaging Initiative.

AJNR Am J Neuroradiol. 2013 Mar;34(3):505-10. doi: 10.3174/ajnr.A3267. Epub 2012 Sep 13.

41.

Amyloid-β--associated clinical decline occurs only in the presence of elevated P-tau.

Desikan RS, McEvoy LK, Thompson WK, Holland D, Brewer JB, Aisen PS, Sperling RA, Dale AM; Alzheimer’s Disease Neuroimaging Initiative.

Arch Neurol. 2012 Jun;69(6):709-13. doi: 10.1001/archneurol.2011.3354.

43.

Interregional correlations in Parkinson disease and Parkinson-related dementia with resting functional MR imaging.

Seibert TM, Murphy EA, Kaestner EJ, Brewer JB.

Radiology. 2012 Apr;263(1):226-34. doi: 10.1148/radiol.12111280. Epub 2012 Feb 27.

44.

Search-Related Suppression of Hippocampus and Default Network Activity during Associative Memory Retrieval.

Reas ET, Gimbel SI, Hales JB, Brewer JB.

Front Hum Neurosci. 2011 Oct 30;5:112. doi: 10.3389/fnhum.2011.00112. eCollection 2011.

45.

Amyloid-β associated volume loss occurs only in the presence of phospho-tau.

Desikan RS, McEvoy LK, Thompson WK, Holland D, Roddey JC, Blennow K, Aisen PS, Brewer JB, Hyman BT, Dale AM; Alzheimer’s Disease Neuroimaging Initiative.

Ann Neurol. 2011 Oct;70(4):657-61. doi: 10.1002/ana.22509. Epub 2011 Oct 14.

46.

Predicting MCI outcome with clinically available MRI and CSF biomarkers.

Heister D, Brewer JB, Magda S, Blennow K, McEvoy LK; Alzheimer's Disease Neuroimaging Initiative.

Neurology. 2011 Oct 25;77(17):1619-28. doi: 10.1212/WNL.0b013e3182343314. Epub 2011 Oct 12.

47.

Stability of resting fMRI interregional correlations analyzed in subject-native space: a one-year longitudinal study in healthy adults and premanifest Huntington's disease.

Seibert TM, Majid DS, Aron AR, Corey-Bloom J, Brewer JB.

Neuroimage. 2012 Feb 1;59(3):2452-63. doi: 10.1016/j.neuroimage.2011.08.105. Epub 2011 Sep 10.

48.

CETP polymorphisms associate with brain structure, atrophy rate, and Alzheimer's disease risk in an APOE-dependent manner.

Murphy EA, Roddey JC, McEvoy LK, Holland D, Hagler DJ Jr, Dale AM, Brewer JB; Alzheimer’s Disease Neuroimaging Initiative.

Brain Imaging Behav. 2012 Mar;6(1):16-26. doi: 10.1007/s11682-011-9137-0.

49.

Default network correlations analyzed on native surfaces.

Seibert TM, Brewer JB.

J Neurosci Methods. 2011 Jun 15;198(2):301-11. doi: 10.1016/j.jneumeth.2011.04.010. Epub 2011 Apr 14.

50.

Mild cognitive impairment: baseline and longitudinal structural MR imaging measures improve predictive prognosis.

McEvoy LK, Holland D, Hagler DJ Jr, Fennema-Notestine C, Brewer JB, Dale AM; Alzheimer's Disease Neuroimaging Initiative.

Radiology. 2011 Jun;259(3):834-43. doi: 10.1148/radiol.11101975. Epub 2011 Apr 6.

Supplemental Content

Loading ...
Support Center